Kura Oncology Inc (NAS:KURA)
$ 8.86 -0.08 (-0.89%) Market Cap: 688.99 Mil Enterprise Value: 250.32 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 29/100

Kura Oncology Inc at Stifel Targeted Oncology Days (Virtual) Transcript

Apr 25, 2023 / 05:00PM GMT
Release Date Price: $10.73 (-0.28%)
Bradley Canino
Stifel - Research Analyst

Thanks, everyone, for continuing to join us for the fireside chat sessions for the Stifel Inaugural Target Oncology Days that I'm hosting with my colleague analysts, Ben Burnett and Steve Willey. Happy to continue this fireside with Kura for this session. Got Troy Wilson, President and CEO, who needs little introduction. So thanks for joining us, Troy.

Questions & Answers

Bradley Canino
Stifel - Research Analyst

And maybe just -- we'll jump right in if you can help us orient the discussion that we're going to have around ziftomenib, your menin inhibitor by discussing some of the ASH '22 data and the priced EHA '23 abstracts that was released -- a degree of efficacy relative to competitors and other targeted therapies. And then really with the abstract focus on the NPM1, what are the key elements that were updated there?

Troy Wilson
Kura Oncology Inc. - President & CEO

Sure, Brad. Let me start by thanking you and Stifel for having this opportunity to chat

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot